Neslihan Kurtulmus1, Burak Ertas2, Yesim Saglican3, Hakan Kaya1, Umit Ince3, Mete Duren1. 1. Endocrinology and Thyroid Clinic, Acibadem Maslak Hospital, Istanbul, Turkey. 2. Otorhinolaryngology, Istanbul, Medical Faculty, Acibadem University, Istanbul, Turkey. 3. Pathology, Medical Faculty, Acibadem University, Istanbul, Turkey.
Abstract
BACKGROUND: The BRAFV600E mutation is common in papillary thyroid cancer (PTC). Lymph node metastasis (LNM) may be associated with poor prognosis. However, the LNM mechanism remains unclear. OBJECTIVES: Our aim was to evaluate the prevalence of the BRAFV600E mutation in primary tumors and accompanying LNM at the time of diagnosis. METHODS: This retrospective study included 51 PTC patients (40 women, 11 men; mean age 40.0 ± 16.5 years; range 6-81) who underwent total thyroidectomy accompanied by a lateral neck dissection due to preoperatively detected LNM. Real-time PCR was used for the detection of the BRAFV600E mutation in specimens from primary thyroid tumors and metastatic lymph node tumors. RESULTS: The prevalence of the BRAFV600E mutation was 64.7% (n = 33) in primary tumors and 47.1% (n = 24) in metastatic lymph nodes. Of 33 patients with BRAFV600E-positive primary tumors, 18 (54.5%) had BRAFV600E-positive metastatic lymph nodes. Of 18 patients with BRAFV600E-negative primary tumors, 6 (33.3%) had BRAFV600E-positive metastatic lymph nodes. The presence of the BRAFV600E mutation in the primary tumor did not affect the tumor size, but the diameter of metastatic lymph nodes significantly increased (by nearly 3 mm) with the presence of BRAFV600E in LNM (p = 0.01). CONCLUSIONS: In our study, the BRAFV600E mutation did not show a one-to-one correspondence. This indicates that the presence of BRAFV600E in the primary tumor is not clonal and addresses the role of intratumor heterogeneity in PTC tumorigenesis. This supports the theses that mutations occur in the later stages of tumorigenesis, might be subclonal, and develop de novo, or that some other factors may be involved in the development of metastasis.
BACKGROUND: The BRAFV600E mutation is common in papillary thyroid cancer (PTC). Lymph node metastasis (LNM) may be associated with poor prognosis. However, the LNM mechanism remains unclear. OBJECTIVES: Our aim was to evaluate the prevalence of the BRAFV600E mutation in primary tumors and accompanying LNM at the time of diagnosis. METHODS: This retrospective study included 51 PTC patients (40 women, 11 men; mean age 40.0 ± 16.5 years; range 6-81) who underwent total thyroidectomy accompanied by a lateral neck dissection due to preoperatively detected LNM. Real-time PCR was used for the detection of the BRAFV600E mutation in specimens from primary thyroid tumors and metastatic lymph node tumors. RESULTS: The prevalence of the BRAFV600E mutation was 64.7% (n = 33) in primary tumors and 47.1% (n = 24) in metastatic lymph nodes. Of 33 patients with BRAFV600E-positive primary tumors, 18 (54.5%) had BRAFV600E-positive metastatic lymph nodes. Of 18 patients with BRAFV600E-negative primary tumors, 6 (33.3%) had BRAFV600E-positive metastatic lymph nodes. The presence of the BRAFV600E mutation in the primary tumor did not affect the tumor size, but the diameter of metastatic lymph nodes significantly increased (by nearly 3 mm) with the presence of BRAFV600E in LNM (p = 0.01). CONCLUSIONS: In our study, the BRAFV600E mutation did not show a one-to-one correspondence. This indicates that the presence of BRAFV600E in the primary tumor is not clonal and addresses the role of intratumor heterogeneity in PTC tumorigenesis. This supports the theses that mutations occur in the later stages of tumorigenesis, might be subclonal, and develop de novo, or that some other factors may be involved in the development of metastasis.
Entities:
Keywords:
BRAFV600E; Metastatic lymph node; Papillary thyroid cancer
Authors: Aleksandra Popadich; Olga Levin; James C Lee; Stephanie Smooke-Praw; Kevin Ro; Maisam Fazel; Asit Arora; Neil S Tolley; Fausto Palazzo; Diana L Learoyd; Stan Sidhu; Leigh Delbridge; Mark Sywak; Michael W Yeh Journal: Surgery Date: 2011-12 Impact factor: 3.982
Authors: Kristian Unger; Horst Zitzelsberger; Giuliana Salvatore; Massimo Santoro; Tatjana Bogdanova; Herbert Braselmann; Peter Kastner; Lyudmilla Zurnadzhy; Nikolay Tronko; Peter Hutzler; Gerry Thomas Journal: J Clin Endocrinol Metab Date: 2004-09 Impact factor: 5.958
Authors: Angela M Costa; Agustín Herrero; Manuel F Fresno; Jonas Heymann; José Antonio Alvarez; Jose Cameselle-Teijeiro; Ginesa García-Rostán Journal: Clin Endocrinol (Oxf) Date: 2007-12-05 Impact factor: 3.478